<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34972208</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>144</Volume><Issue>12</Issue><PubDate><Year>2021</Year><Month>Dec</Month><Day>31</Day></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>Defective cyclophilin A induces TDP-43 proteinopathy: implications for amyotrophic lateral sclerosis and frontotemporal dementia.</ArticleTitle><Pagination><StartPage>3710</StartPage><EndPage>3726</EndPage><MedlinePgn>3710-3726</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awab333</ELocationID><Abstract><AbstractText>Aggregation and cytoplasmic mislocalization of TDP-43 are pathological hallmarks of amyotrophic lateral sclerosis and frontotemporal dementia spectrum. However, the molecular mechanism by which TDP-43 aggregates form and cause neurodegeneration remains poorly understood. Cyclophilin A, also known as peptidyl-prolyl cis-trans isomerase A (PPIA), is a foldase and molecular chaperone. We previously found that PPIA interacts with TDP-43 and governs some of its functions, and its deficiency accelerates disease in a mouse model of amyotrophic lateral sclerosis. Here we characterized PPIA knock-out mice throughout their lifespan and found that they develop a neurodegenerative disease with key behavioural features of frontotemporal dementia, marked TDP-43 pathology and late-onset motor dysfunction. In the mouse brain, deficient PPIA induces mislocalization and aggregation of the GTP-binding nuclear protein Ran, a PPIA interactor and a master regulator of nucleocytoplasmic transport, also for TDP-43. Moreover, in absence of PPIA, TDP-43 autoregulation is perturbed and TDP-43 and proteins involved in synaptic function are downregulated, leading to impairment of synaptic plasticity. Finally, we found that PPIA was downregulated in several patients with amyotrophic lateral sclerosis and amyotrophic lateral sclerosis-frontotemporal dementia, and identified a PPIA loss-of-function mutation in a patient with sporadic amyotrophic lateral sclerosis . The mutant PPIA has low stability, altered structure and impaired interaction with TDP-43. These findings strongly implicate that defective PPIA function causes TDP-43 mislocalization and dysfunction and should be considered in future therapeutic approaches.</AbstractText><CopyrightInformation>&#xa9; The Author(s) (2021). Published by Oxford University Press on behalf of the Guarantors of Brain.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pasetto</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grassano</LastName><ForeName>Maurizio</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>'Rita Levi Montalcini' Department of Neuroscience, University of Torino, Torino, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pozzi</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>CERVO Brain Research Centre, Qu&#xe9;bec City, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luotti</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sammali</LastName><ForeName>Eliana</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Migazzi</LastName><ForeName>Alice</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Trento, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basso</LastName><ForeName>Manuela</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-9278-8960</Identifier><AffiliationInfo><Affiliation>Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milano, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Trento, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spagnolli</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Trento, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dulbecco Telethon Institute, University of Trento, Trento, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biasini</LastName><ForeName>Emiliano</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Trento, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dulbecco Telethon Institute, University of Trento, Trento, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Micotti</LastName><ForeName>Edoardo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cerovic</LastName><ForeName>Milica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carli</LastName><ForeName>Mirjana</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forloni</LastName><ForeName>Gianluigi</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-5374-3914</Identifier><AffiliationInfo><Affiliation>Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Marco</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-3966-8695</Identifier><AffiliationInfo><Affiliation>'Rita Levi Montalcini' Department of Neuroscience, University of Torino, Torino, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manera</LastName><ForeName>Umberto</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>'Rita Levi Montalcini' Department of Neuroscience, University of Torino, Torino, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moglia</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>'Rita Levi Montalcini' Department of Neuroscience, University of Torino, Torino, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mora</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurorehabilitation, ICS Maugeri IRCCS, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Traynor</LastName><ForeName>Bryan J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Neuromuscular Diseases Research Section, Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University Medical Center, Baltimore, MD 21287, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Reta Lila Weston Institute, UCL Queen Square Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chi&#xf2;</LastName><ForeName>Adriano</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>'Rita Levi Montalcini' Department of Neuroscience, University of Torino, Torino, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calvo</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-5122-7243</Identifier><AffiliationInfo><Affiliation>'Rita Levi Montalcini' Department of Neuroscience, University of Torino, Torino, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonetto</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0003-0456-2054</Identifier><AffiliationInfo><Affiliation>Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milano, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ZIA AG000935</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 5.2.1.-</RegistryNumber><NameOfSubstance UI="D021984">Cyclophilin A</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021984" MajorTopicYN="N">Cyclophilin A</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">FTD</Keyword><Keyword MajorTopicYN="N">Ran</Keyword><Keyword MajorTopicYN="N">TDP-43 pathology</Keyword><Keyword MajorTopicYN="N">mouse model</Keyword><Keyword MajorTopicYN="N">nucleocytoplasmic transport</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>31</Day><Hour>20</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34972208</ArticleId><ArticleId IdType="pmc">PMC8719849</ArticleId><ArticleId IdType="doi">10.1093/brain/awab333</ArticleId><ArticleId IdType="pii">6491324</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ratti A, Buratti E. &#xa0;Physiological functions and pathobiology of TDP-43 and FUS/TLS proteins. J Neurochem. 2016;138 (Suppl 1):95&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">27015757</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala YM, De Conti L, Avenda&#xf1;o-V&#xe1;zquez SE, et al. &#xa0;TDP-43 regulates its mRNA levels through a negative feedback loop. EMBO J. 2011;30(2):277&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3025456</ArticleId><ArticleId IdType="pubmed">21131904</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymenidou M, Lagier-Tourenne C, Hutt KR, et al. &#xa0;Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci. 2011;14(4):459&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3094729</ArticleId><ArticleId IdType="pubmed">21358643</ArticleId></ArticleIdList></Reference><Reference><Citation>de Boer EMJ, Orie VK, Williams T, et al. &#xa0;TDP-43 proteinopathies: A new wave of neurodegenerative diseases. J Neurol Neurosurg Psychiatry. 2020;92(1):86&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7803890</ArticleId><ArticleId IdType="pubmed">33177049</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, et al. &#xa0;Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>De Marco G, Lupino E, Calvo A, et al. &#xa0;Cytoplasmic accumulation of TDP-43 in circulating lymphomonocytes of ALS patients with and without TARDBP mutations. Acta Neuropathol. 2011;121(5):611&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pubmed">21120508</ArticleId></ArticleIdList></Reference><Reference><Citation>Luotti S, Pasetto L, Porcu L, et al. &#xa0;Diagnostic and prognostic values of PBMC proteins in amyotrophic lateral sclerosis. Neurobiol Dis. &#xa0;2020;139:104815.</Citation><ArticleIdList><ArticleId IdType="pubmed">32087285</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L, Kim HJ, Wang H, et al. &#xa0;Nuclear-import receptors reverse aberrant phase transitions of RNA-binding proteins with prion-like domains. Cell. 2018;173(3):677&#x2013;692.e20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5911940</ArticleId><ArticleId IdType="pubmed">29677512</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, Taylor JP. &#xa0;Lost in transportation: Nucleocytoplasmic transport defects in ALS and other neurodegenerative diseases. Neuron. 2017;96(2):285&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5678982</ArticleId><ArticleId IdType="pubmed">29024655</ArticleId></ArticleIdList></Reference><Reference><Citation>Tziortzouda P, Van Den Bosch L, Hirth F. &#xa0;Triad of TDP43 control in neurodegeneration: Autoregulation, localization and aggregation. Nat Rev Neurosci. 2021;22(4):197&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">33654312</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryffel B, Woerly G, Greiner B, Haendler B, Mihatsch MJ, Foxwell BM. &#xa0;Distribution of the cyclosporine binding protein cyclophilin in human tissues. Immunology. 1991;72(3):399&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1384402</ArticleId><ArticleId IdType="pubmed">2026447</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer G, Wittmann-Liebold B, Lang K, Kiefhaber T, Schmid FX. &#xa0;Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins. Nature. 1989;337(6206):476&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pubmed">2492638</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauranzano E, Pozzi S, Pasetto L, et al. &#xa0;Peptidylprolyl isomerase A governs TARDBP function and assembly in heterogeneous nuclear ribonucleoprotein complexes. Brain. 2015;138(Pt 4):974&#x2013;991.</Citation><ArticleIdList><ArticleId IdType="pubmed">25678563</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JP, Palfrey HC, Bindokas VP, et al. &#xa0;The role of immunophilins in mutant superoxide dismutase-1linked familial amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 1999;96(6):3251&#x2013;3256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15928</ArticleId><ArticleId IdType="pubmed">10077670</ArticleId></ArticleIdList></Reference><Reference><Citation>Boulos S, Meloni BP, Arthur PG, Majda B, Bojarski C, Knuckey NW. &#xa0;Evidence that intracellular cyclophilin A and cyclophilin A/CD147 receptor-mediated ERK1/2 signalling can protect neurons against in vitro oxidative and ischemic injury. Neurobiol Dis. 2007;25(1):54&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">17011206</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan H, Luo C, Li R, et al. &#xa0;Cyclophilin A is required for CXCR4-mediated nuclear export of heterogeneous nuclear ribonucleoprotein A2, activation and nuclear translocation of ERK1/2, and chemotactic cell migration. J Biol Chem. 2008;283(1):623&#x2013;637.</Citation><ArticleIdList><ArticleId IdType="pubmed">17991743</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherry B, Yarlett N, Strupp A, Cerami A. &#xa0;Identification of cyclophilin as a proinflammatory secretory product of lipopolysaccharide-activated macrophages. Proc Natl Acad Sci U S A. 1992;89(8):3511&#x2013;3515.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC48898</ArticleId><ArticleId IdType="pubmed">1565646</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasetto L, Pozzi S, Castelnovo M, et al. &#xa0;Targeting extracellular cyclophilin A reduces neuroinflammation and extends survival in a mouse model of amyotrophic lateral sclerosis. J Neurosci. 2017;37(6):1413&#x2013;1427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6705677</ArticleId><ArticleId IdType="pubmed">28011744</ArticleId></ArticleIdList></Reference><Reference><Citation>Nigro P, Pompilio G, Capogrossi MC. &#xa0;Cyclophilin A: A key player for human disease. Cell Death Dis. 2013;4:e888.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3920964</ArticleId><ArticleId IdType="pubmed">24176846</ArticleId></ArticleIdList></Reference><Reference><Citation>Basso M, Samengo G, Nardo G, et al. &#xa0;Characterization of detergent-insoluble proteins in ALS indicates a causal link between nitrative stress and aggregation in pathogenesis. PLoS One. 2009;4(12):e8130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2780298</ArticleId><ArticleId IdType="pubmed">19956584</ArticleId></ArticleIdList></Reference><Reference><Citation>Massignan T, Casoni F, Basso M, et al. &#xa0;Proteomic analysis of spinal cord of presymptomatic amyotrophic lateral sclerosis G93A SOD1 mouse. Biochem Biophys Res Commun. 2007;353(3):719&#x2013;725.</Citation><ArticleIdList><ArticleId IdType="pubmed">17196550</ArticleId></ArticleIdList></Reference><Reference><Citation>Nardo G, Pozzi S, Pignataro M, et al. &#xa0;Amyotrophic lateral sclerosis multiprotein biomarkers in peripheral blood mononuclear cells. PLoS ONE. 2011;6(10):e25545.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3187793</ArticleId><ArticleId IdType="pubmed">21998667</ArticleId></ArticleIdList></Reference><Reference><Citation>Filareti M, Luotti S, Pasetto L, et al. &#xa0;Decreased levels of foldase and chaperone proteins are associated with an early-onset amyotrophic lateral sclerosis. Front Mol Neurosci. 2017;10:99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5382314</ArticleId><ArticleId IdType="pubmed">28428745</ArticleId></ArticleIdList></Reference><Reference><Citation>Colgan J, Asmal M, Luban J. &#xa0;Isolation, characterization and targeted disruption of mouse ppia: Cyclophilin A is not essential for mammalian cell viability. Genomics. 2000;68(2):167&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">10964515</ArticleId></ArticleIdList></Reference><Reference><Citation>Colgan J, Asmal M, Neagu M, et al. &#xa0;Cyclophilin A regulates TCR signal strength in CD4+ T cells via a proline-directed conformational switch in Itk. Immunity. 2004;21(2):189&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">15308100</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancini S, Balducci C, Micotti E, et al. &#xa0;Multifunctional liposomes delay phenotype progression and prevent memory impairment in a presymptomatic stage mouse model of Alzheimer disease. J Controlled Release. 2017;258:121&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">28501671</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasetto L, Olivari D, Nardo G, et al. &#xa0;Micro-computed tomography for non-invasive evaluation of muscle atrophy in mouse models of disease. PLoS ONE. 2018;13(5):e0198089.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5973599</ArticleId><ArticleId IdType="pubmed">29813127</ArticleId></ArticleIdList></Reference><Reference><Citation>Nardo G, Trolese MC, de Vito G, et al. &#xa0;Immune response in peripheral axons delays disease progression in SOD1(G93A) mice. J Neuroinflammation. 2016;13(1):261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5055725</ArticleId><ArticleId IdType="pubmed">27717377</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Mot Neuron Disord. 2000;1(5):293&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Iazzolino B, Peotta L, Zucchetti JP, et al. &#xa0;Differential neuropsychological profile of patients with amyotrophic lateral sclerosis with and without C9orf72 mutation. Neurology. 2021;96(1):e141&#x2013;e152.</Citation><ArticleIdList><ArticleId IdType="pubmed">33106391</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascovsky K, Hodges JR, Knopman D, et al. &#xa0;Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 9):2456&#x2013;2477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170532</ArticleId><ArticleId IdType="pubmed">21810890</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, Abrahams S, Goldstein LH, et al. &#xa0;Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. Amyotroph Lateral Scler Front Degener. 2017;18(3-4):153&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7409990</ArticleId><ArticleId IdType="pubmed">28054827</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersen EF, Goddard TD, Huang CC, et al. &#xa0;UCSF Chimera&#x2013;a visualization system for exploratory research and analysis. J Comput Chem. 2004;25(13):1605&#x2013;1612.</Citation><ArticleIdList><ArticleId IdType="pubmed">15264254</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, Lee VM-Y, Trojanowski JQ. &#xa0;Gains or losses: Molecular mechanisms of TDP43-mediated neurodegeneration. Nat Rev Neurosci. 2011;13(1):38&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3285250</ArticleId><ArticleId IdType="pubmed">22127299</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Zhang Y-J, Baker M, Rademakers R, Petrucelli L, Dickson DW. &#xa0;C-terminal and full length TDP-43 specie differ according to FTLD-TDP lesion type but not genetic mutation. Acta Neuropathol Commun. 2019;7(1):100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6607585</ArticleId><ArticleId IdType="pubmed">31266542</ArticleId></ArticleIdList></Reference><Reference><Citation>Cicardi ME, Cristofani R, Rusmini P, et al. &#xa0;Tdp-25 routing to autophagy and proteasome ameliorates its aggregation in amyotrophic lateral sclerosis target cells. Sci Rep. 2018;8(1):12390.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6098007</ArticleId><ArticleId IdType="pubmed">30120266</ArticleId></ArticleIdList></Reference><Reference><Citation>Goossens J, Vanmechelen E, Trojanowski JQ, et al. &#xa0;TDP-43 as a possible biomarker for frontotemporal lobar degeneration: A systematic review of existing antibodies. Acta Neuropathol Commun. 2015;3:15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4380254</ArticleId><ArticleId IdType="pubmed">25853864</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M, Arai T, Nonaka T, et al. &#xa0;Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol. 2008;64(1):60&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2674108</ArticleId><ArticleId IdType="pubmed">18546284</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Kwong LK, Lee EB, et al. &#xa0;Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol. 2009;117(2):137&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2693625</ArticleId><ArticleId IdType="pubmed">19125255</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward ME, Taubes A, Chen R, et al. &#xa0;Early retinal neurodegeneration and impaired Ran-mediated nuclear import of TDP-43 in progranulin-deficient FTLD. J Exp Med. 2014;211(10):1937&#x2013;1945.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4172214</ArticleId><ArticleId IdType="pubmed">25155018</ArticleId></ArticleIdList></Reference><Reference><Citation>Petkau TL, Neal SJ, Milnerwood A, et al. &#xa0;Synaptic dysfunction in progranulin-deficient mice. Neurobiol Dis. 2012;45(2):711&#x2013;722.</Citation><ArticleIdList><ArticleId IdType="pubmed">22062772</ArticleId></ArticleIdList></Reference><Reference><Citation>Colombrita C, Onesto E, Megiorni F, et al. &#xa0;TDP-43 and FUS RNA-binding proteins bind distinct sets of cytoplasmic messenger RNAs and differently regulate their post-transcriptional fate in motoneuron-like cells. J Biol Chem. 2012;287(19):15635&#x2013;15647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3346140</ArticleId><ArticleId IdType="pubmed">22427648</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks SP, Pask T, Jones L, Dunnett SB. &#xa0;Behavioural profiles of inbred mouse strains used as transgenic backgrounds. II: Cognitive tests. Genes Brain Behav. 2005;4(5):307&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pubmed">16011577</ArticleId></ArticleIdList></Reference><Reference><Citation>Vernay A, Sellal F, Ren&#xe9; F. &#xa0;Evaluating behavior in mouse models of the behavioral variant of frontotemporal dementia: Which test for which symptom? &#xa0;Neurodegener Dis. 2016;16(3-4):127&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">26517704</ArticleId></ArticleIdList></Reference><Reference><Citation>de Souza LC, Chupin M, Bertoux M, et al. &#xa0;Is hippocampal volume a good marker to differentiate Alzheimer&#x2019;s disease from frontotemporal dementia? &#xa0;J Alzheimers Dis. 2013;36(1):57&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">23542864</ArticleId></ArticleIdList></Reference><Reference><Citation>von Hahn T, Ciesek S. &#xa0;Cyclophilin polymorphism and virus infection. Curr Opin Virol. 2015;14:47&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102842</ArticleId><ArticleId IdType="pubmed">26281011</ArticleId></ArticleIdList></Reference><Reference><Citation>Howard BR, Vajdos FF, Li S, Sundquist WI, Hill CP. &#xa0;Structural insights into the catalytic mechanism of cyclophilin A. Nat Struct Biol. 2003;10(6):475&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pubmed">12730686</ArticleId></ArticleIdList></Reference><Reference><Citation>Seyfried NT, Gozal YM, Donovan LE, et al. &#xa0;Quantitative analysis of the detergent-insoluble brain proteome in frontotemporal lobar degeneration using SILAC internal standards. J Proteome Res. 2012;11(5):2721&#x2013;2738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3357000</ArticleId><ArticleId IdType="pubmed">22416763</ArticleId></ArticleIdList></Reference><Reference><Citation>Blokhuis AM, Koppers M, Groen EJN, et al. &#xa0;Comparative interactomics analysis of different ALS-associated proteins identifies converging molecular pathways. Acta Neuropathol. 2016;132(2):175&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4947123</ArticleId><ArticleId IdType="pubmed">27164932</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee K-H, Zhang P, Kim HJ, et al. &#xa0;C9orf72 dipeptide repeats impair the assembly, dynamics, and function of membrane-less organelles. Cell. 2016;167(3):774&#x2013;788.e17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5079111</ArticleId><ArticleId IdType="pubmed">27768896</ArticleId></ArticleIdList></Reference><Reference><Citation>Yurchenko V, Zybarth G, O'Connor M, et al. &#xa0;Active site residues of cyclophilin A are crucial for its signaling activity via CD147. J Biol Chem. 2002;277(25):22959&#x2013;22965.</Citation><ArticleIdList><ArticleId IdType="pubmed">11943775</ArticleId></ArticleIdList></Reference><Reference><Citation>Piotukh K, Gu W, Kofler M, Labudde D, Helms V, Freund C. &#xa0;Cyclophilin A binds to linear peptide motifs containing a consensus that is present in many human proteins. J Biol Chem. 2005;280(25):23668&#x2013;23674.</Citation><ArticleIdList><ArticleId IdType="pubmed">15845542</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou C-C, Zhang Y, Umoh ME, et al. &#xa0;TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD. Nat Neurosci. 2018;21(2):228&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5800968</ArticleId><ArticleId IdType="pubmed">29311743</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasset-Rosa F, Lu S, Yu H, et al. &#xa0;Cytoplasmic TDP-43 de-mixing independent of stress granules drives inhibition of nuclear import, loss of nuclear TDP-43, and cell death. Neuron. 2019;102(2):339&#x2013;357.e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6548321</ArticleId><ArticleId IdType="pubmed">30853299</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Daigle JG, Cunningham KM, et al. &#xa0;Stress granule assembly disrupts nucleocytoplasmic transport. Cell. 2018;173(4):958&#x2013;971.e17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6083872</ArticleId><ArticleId IdType="pubmed">29628143</ArticleId></ArticleIdList></Reference><Reference><Citation>White MA, Kim E, Duffy A, et al. &#xa0;TDP-43 gains function due to perturbed autoregulation in a Tardbp knock-in mouse model of ALS-FTD. Nat Neurosci. 2018;21(4):552&#x2013;563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5884423</ArticleId><ArticleId IdType="pubmed">29556029</ArticleId></ArticleIdList></Reference><Reference><Citation>Castello A, Fischer B, Eichelbaum K, et al. &#xa0;Insights into RNA biology from an atlas of mammalian mRNA-binding proteins. Cell. 2012;149(6):1393&#x2013;1406.</Citation><ArticleIdList><ArticleId IdType="pubmed">22658674</ArticleId></ArticleIdList></Reference><Reference><Citation>Iguchi Y, Katsuno M, Niwa J, et al. &#xa0;Loss of TDP-43 causes age-dependent progressive motor neuron degeneration. Brain. 2013;136(Pt 5):1371&#x2013;1382.</Citation><ArticleIdList><ArticleId IdType="pubmed">23449777</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu L-S, Cheng W-C, Shen C-KJ. &#xa0;Targeted depletion of TDP-43 expression in the spinal cord motor neurons leads to the development of amyotrophic lateral sclerosis-like phenotypes in mice. J Biol Chem. 2012;287(33):27335&#x2013;27344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3431639</ArticleId><ArticleId IdType="pubmed">22718760</ArticleId></ArticleIdList></Reference><Reference><Citation>Sephton CF, Cenik C, Kucukural A, et al. &#xa0;Identification of neuronal RNA targets of TDP-43-containing ribonucleoprotein complexes. J Biol Chem. 2011;286(2):1204&#x2013;1215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3020728</ArticleId><ArticleId IdType="pubmed">21051541</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann H, Schiene-Fischer C. &#xa0;Functional aspects of extracellular cyclophilins. Biol Chem. 2014;395(7-8):721&#x2013;735.</Citation><ArticleIdList><ArticleId IdType="pubmed">24713575</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan A, Spiller KJ, Towne C, et al. &#xa0;Neuronal matrix metalloproteinase-9 is a determinant of selective neurodegeneration. Neuron. 2014;81(2):333&#x2013;348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6015650</ArticleId><ArticleId IdType="pubmed">24462097</ArticleId></ArticleIdList></Reference><Reference><Citation>Beuche W, Yushchenko M, Mader M, Maliszewska M, Felgenhauer K, Weber F. &#xa0;Matrix metalloproteinase-9 is elevated in serum of patients with amyotrophic lateral sclerosis. Neuroreport. 2000;11(16):3419&#x2013;3422.</Citation><ArticleIdList><ArticleId IdType="pubmed">11095490</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang L, Huber-Abel F, Teuchert M, et al. &#xa0;Linking neuron and skin: Matrix metalloproteinases in amyotrophic lateral sclerosis (ALS). J Neurol Sci. 2009;285(1-2):62&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">19523650</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell RD, Winkler EA, Singh I, et al. &#xa0;Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature. 2012;485(7399):512&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4047116</ArticleId><ArticleId IdType="pubmed">22622580</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon DA, Mitchell JC, Salcher-Konrad M-T, Vance CA, Mizielinska S. &#xa0;Review: Modelling the pathology and behaviour of frontotemporal dementia. Neuropathol Appl Neurobiol. 2019;45(1):58&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">30582188</ArticleId></ArticleIdList></Reference><Reference><Citation>Berning BA, Walker AK. &#xa0;The pathobiology of TDP-43 C-terminal fragments in ALS and FTLD. Front Neurosci. 2019;13:335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6470282</ArticleId><ArticleId IdType="pubmed">31031584</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Ber I, Guedj E, Gabelle A, et al. &#xa0;Demographic, neurological and behavioural characteristics and brain perfusion SPECT in frontal variant of frontotemporal dementia. Brain J Neurol. 2006;129(11):3051&#x2013;3065.</Citation><ArticleIdList><ArticleId IdType="pubmed">17071924</ArticleId></ArticleIdList></Reference><Reference><Citation>Bersano E, Sarnelli MF, Solara V, et al. &#xa0;Decline of cognitive and behavioral functions in amyotrophic lateral sclerosis: A longitudinal study. Amyotroph Lateral Scler Front Degener. 2020;21(5-6):373&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pubmed">32484726</ArticleId></ArticleIdList></Reference><Reference><Citation>Burrell JR, Kiernan MC, Vucic S, Hodges JR. &#xa0;Motor neuron dysfunction in frontotemporal dementia. Brain. 2011;134(Pt 9):2582&#x2013;2594.</Citation><ArticleIdList><ArticleId IdType="pubmed">21840887</ArticleId></ArticleIdList></Reference><Reference><Citation>Lul&#xe9; DE, Aho-&#xd6;zhan HEA, V&#xe1;zquez C, et al. &#xa0;Story of the ALS-FTD continuum retold: Rather two distinct entities. J Neurol Neurosurg Psychiatry. 2019;90(5):586&#x2013;589.</Citation><ArticleIdList><ArticleId IdType="pubmed">30257969</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker M, Mackenzie IR, Pickering-Brown SM, et al. &#xa0;Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature. 2006;442(7105):916&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">16862116</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghezzi P, Casagrande S, Massignan T, et al. &#xa0;Redox regulation of cyclophilin A by glutathionylation. Proteomics. 2006;6(3):817&#x2013;825.</Citation><ArticleIdList><ArticleId IdType="pubmed">16372262</ArticleId></ArticleIdList></Reference><Reference><Citation>Lammers M, Neumann H, Chin JW, James LC. &#xa0;Acetylation regulates cyclophilin A catalysis, immunosuppression and HIV isomerization. Nat Chem Biol. 2010;6(5):331&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3867001</ArticleId><ArticleId IdType="pubmed">20364129</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>